XML 32 R20.htm IDEA: XBRL DOCUMENT v3.25.1
LICENSING AGREEMENTS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Feb. 28, 2022
Dec. 28, 2020
May 17, 2017
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Aug. 31, 2023
Sep. 30, 2021
Jan. 31, 2021
Dec. 31, 2020
Dec. 12, 2020
Feb. 02, 2016
Number of shares                       43,112
Initial payment       $ 100,000                
Cash payment       50,000                
Payment for clinical trial       200,000                
Common Stock Value       2,586   $ 1,749           $ 100,000
Total obligation under the agreement       $ 300,000       $ 300,000   $ 100,000 $ 300,000  
Common stock, shares, issued       2,585,532   1,748,428            
Initial payment of obligation               $ 40,000   50,000 $ 50,000  
Balance of obligation, description       The remaining portion of the $300,000 obligation was paid in cash in 2020                
Remaining portion of obligation             $ 100,000          
Amortization expenses       $ 30,577 $ 29,271              
Amortization expenses       11,485 11,485              
Amortization       46,000                
Description of payment on conversion basis     Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date                  
Description for the consecutive trading days     In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles                  
Payments upon completion of the IRB clinical trial     $ 200,000                  
Payments in the event of commercialization of technology       300,000                
Licensing Agreements [Member]                        
Payments upon dosing of the first patient in Phase 3 clinical trial       200,000                
Patents [Member]                        
Carrying value of patent       53,009                
License Agreement [Member]                        
Amortization expenses       293 293              
Amortization       563                
Carrying value of patent       $ 568                
ImmCelz Patent [Member]                        
Common Stock, shares               8,466 8,929   667  
Discount Rate       25.00%                
Amortization expenses       $ 4,929 0              
Amortization       $ 20,000                
Interest rate       5.00%                
Royalty percentage rate       5.00%                
Carrying value of patent       $ 190,033                
Exercise Price       $ 0.0037                
EDI Patent [Member]                        
Amortization expenses       $ 2,493 2,493              
Amortization       9,972                
Carrying value of patent       8,576                
IND [Member]                        
Amortization expenses       2,463 2,490              
Amortization       25,000                
Carrying value of patent       $ 85,021                
Lower Back Patent [Member]                        
Balance of obligation, description       Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.                
CMH [Member]                        
Total obligation under the agreement                   $ 300,000    
Common stock, shares, issued                   14    
Option Warrant [Member]                        
Initial payment     100,000                  
Amortization expenses       $ 6,250 6,250              
Amortization       25,000                
Carrying value of patent       143,750                
Payments upon dosing of the first patient in Phase 3 clinical trial     400,000 100,000                
Payments upon dosing of the first patient first patient in a Phase 1-2 clinical trial     $ 200,000                  
Jadi Cell [Member]                        
Pyment For License fees $ 250,000 $ 250,000                    
Common stock, shares, issued 18,018                      
StemSpine LLC [Member]                        
Amortization expenses       2,500 $ 2,500              
Amortization       10,000                
Carrying value of patent       25,000                
Value of initial patent license       $ 22,500                
Expiration period of finite-lived intangible assets       May 19, 2027